| Literature DB >> 19083283 |
Mehrul Hasnain1, W Victor R Vieweg, Sonja K Fredrickson, Mary Beatty-Brooks, Antony Fernandez, Anand K Pandurangi.
Abstract
Individuals with major mental illness are a high-risk group for cardio-metabolic derangements due to genetic predisposition, developmental and environmental stressors, and lifestyle. This risk is compounded when they receive antipsychotic medications. Guidelines for screening, monitoring, and managing these patients for metabolic problems have been in place for several years. Despite this, recent reports document that this population continues to receive poor care in this regard. In this article, we review the metabolic profile of atypical antipsychotic medications and offer guidelines to reduce the metabolic complications of these agents.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19083283 DOI： 10.1016/j.pcd.2008.10.005
Source DB: PubMed Journal: Prim Care Diabetes ISSN： 1878-0210 Impact factor: 2.459